The Treatment of Onychophosis in the Foot

Onychophosis is a dermatological condition affecting the toenails, characterised by the hyperkeratotic accumulation of callus tissue within the nail grooves — the lateral and proximal sulci that border the nail plate. Though frequently overlooked or mistaken for other nail pathologies such as onychocryptosis (ingrown toenail) or subungual hyperkeratosis, onychophosis represents a distinct clinical entity that demands targeted management. The condition can cause significant discomfort, particularly in elderly or diabetic populations, and when left untreated, may progress to ulceration, infection, or impaired mobility. Understanding its causes, clinical presentation, and the range of available treatments is essential for effective podiatric care.

Understanding the Condition

The term onychophosis derives from the Greek words for nail (onyx) and callus (phosis), reflecting its defining feature: a localised build-up of hyperkeratotic tissue. This overgrowth occurs primarily in response to chronic mechanical pressure and friction between the nail plate and the surrounding soft tissue of the nail groove. Ill-fitting footwear is among the most common precipitating factors, as narrow toe boxes or excessive pressure from socks and hosiery concentrate force along the nail borders. Biomechanical abnormalities, including hallux valgus, hammer toe deformities, and altered gait patterns, further predispose individuals to this condition by redirecting pressure onto vulnerable nail sulci.

The great toe is most commonly affected, though any digit may develop onychophosis. Patients typically present with pain or tenderness along the nail groove, a sensation of pressure under or beside the nail, and visible thickening of the periungual skin. In severe or long-standing cases, the hyperkeratotic tissue may become macerated, fissured, or secondarily infected, introducing a risk of cellulitis or deeper soft tissue complications, particularly in those with diabetes mellitus or peripheral vascular disease.

Conservative Treatment Approaches

The cornerstone of onychophosis management is conservative, non-surgical debridement, which aims to remove the accumulated keratinous tissue and relieve pressure. This procedure is typically performed by a trained podiatrist using a scalpel, curette, or nail rasp. The practitioner carefully removes the hyperkeratotic material from within the nail sulcus without disrupting the nail matrix or surrounding healthy tissue. Regular debridement — often every six to twelve weeks depending on the rate of recurrence — is effective in managing symptoms and preventing progression for most patients.

Alongside debridement, podiatrists frequently apply emollients and keratolytic agents to soften the thickened tissue and reduce the likelihood of rapid regrowth. Preparations containing urea (typically in concentrations of 10–40%), salicylic acid, or lactic acid are commonly employed. These agents work by disrupting the protein bonds within the keratinised tissue, making it more pliable and amenable to mechanical removal. Patients are often instructed to apply these preparations at home between clinical appointments to maintain tissue suppleness and extend the interval between treatments.

Nail care and patient education are critical adjuncts to clinical treatment. Appropriate nail-cutting technique — trimming straight across rather than in a curved fashion that might encourage lateral nail spicule formation — can reduce mechanical irritation within the groove. Attention to footwear is equally important. Patients should be counselled to wear shoes with adequate toe box depth and width, ensuring that no undue pressure is applied to the nail borders during ambulation. Orthotic devices, toe props, or silicone nail sulcus protectors may be used to redistribute pressure away from the affected grooves, providing both symptomatic relief and a prophylactic benefit.

Advanced Conservative and Adjunctive Therapies

Where standard debridement and topical therapy are insufficient, several more advanced conservative interventions may be considered. Nail bracing, a technique more commonly associated with the management of involuted nails, has been applied with some success in onychophosis by reducing the transverse curvature of the nail plate and thereby alleviating pressure on the lateral sulci. Adhesive brace systems are bonded across the nail surface and gradually flatten the nail’s curvature over several weeks to months. While evidence for their use specifically in onychophosis is limited compared to ingrown nail conditions, the mechanical rationale is sound and the intervention is minimally invasive.

Padding and strapping techniques can also offer temporary but meaningful relief. Felt or foam padding placed adjacent to the nail groove deflects external pressure, while adhesive strapping of the digit can help stabilise soft tissue and reduce shear forces during weight-bearing activities. These methods are particularly valuable as interim measures while longer-term orthopaedic or footwear modifications are implemented.

Surgical and Procedural Interventions

In cases where conservative management fails to provide lasting relief, or where the structural anatomy of the toe perpetuates recurrent onychophosis, surgical options may be warranted. A partial nail avulsion — the removal of the affected lateral strip of nail — can be performed under local anaesthesia to eliminate the nail edge that contributes to sulcus pressure. This procedure is often combined with phenolisation of the nail matrix, in which phenol is applied to the avulsed nail matrix to permanently ablate that portion and prevent regrowth of the offending nail border. This combined partial nail avulsion and phenolisation approach carries a high success rate and low recurrence when performed correctly, making it a reliable option for patients who have not responded adequately to conservative care.

In patients with significant bony deformity contributing to recurrent onychophosis — such as prominent condyles of the distal phalanx or pronounced digital contractures — referral for orthopaedic or podiatric surgical assessment may be appropriate. Procedures such as digital arthroplasty or condylectomy can address the underlying structural causes, potentially offering a more definitive resolution.

Special Considerations in High-Risk Populations

Management of onychophosis in patients with diabetes mellitus, peripheral arterial disease, or immunosuppression requires particular care. In these populations, even minor trauma to the periungual tissue carries heightened risk of infection, ulceration, or impaired wound healing. Debridement should be performed with great caution, using sterile instruments and minimal tissue disruption. Phenolisation is relatively contraindicated in the presence of significant ischaemia, as wound healing may be compromised. Regular podiatric monitoring, appropriate vascular assessment, and multidisciplinary collaboration are essential components of care in these individuals.

Final Word

Onychophosis, while not life-threatening in the majority of patients, can significantly impair quality of life through chronic pain, restricted mobility, and susceptibility to secondary infection. A thorough clinical assessment, tailored to the individual’s anatomy, lifestyle, footwear habits, and comorbidities, underpins effective treatment. Conservative debridement supported by keratolytic agents, footwear modification, and patient education remains the mainstay of management. Where these measures are insufficient, surgical nail procedures or structural corrections offer durable solutions. As with many podiatric conditions, prevention — through appropriate footwear, regular professional nail care, and prompt attention to early symptoms — remains the most powerful tool available.

Overpronation in Runners: Understanding and Treating a Common Biomechanical Problem

Pronation is a natural and necessary motion of the foot. With every step, the foot rolls inward slightly upon landing, absorbing shock and distributing force across the foot and lower limb. This is a fundamental part of healthy gait mechanics. Overpronation, however, occurs when this inward rolling is excessive — the arch collapses further than it should, the ankle rolls inward past its neutral position, and the biomechanical chain running up through the knee, hip, and lower back is disrupted. For runners, who subject their bodies to thousands of repetitive foot strikes per session, overpronation can be the origin point of a range of painful and debilitating injuries. Understanding how to treat and manage this condition is essential knowledge for any serious runner, coach, or clinician working in sports medicine.

The Biomechanical Consequences of Overpronation

To appreciate why treatment matters, it helps to understand what overpronation actually does to the body. When the foot excessively rolls inward, the tibia (shinbone) internally rotates to compensate. This creates a twisting force at the knee, placing undue stress on the medial structures of the joint. Further up the chain, the hip abductors must work harder to stabilise the pelvis, often becoming fatigued and leading to altered pelvic mechanics. Common injuries associated with overpronation include plantar fasciitis, medial tibial stress syndrome (shin splints), patellofemoral pain syndrome (runner’s knee), iliotibial band syndrome, and Achilles tendinopathy. None of these conditions are trivial, and all of them have overpronation as a recognised contributing factor.

Overpronation can result from a variety of structural causes, including flat feet (pes planus), ligamentous laxity, leg length discrepancies, or simple genetic predisposition. It can also be functional — arising from weakness or tightness in specific muscles rather than bony structure — which has important implications for how it should be treated.

Assessment and Diagnosis

Before treatment can begin, the presence and degree of overpronation must be properly assessed. A visual gait analysis — watching the runner from behind as they walk or run on a treadmill — can reveal excessive inward rolling of the ankle and arch collapse. More sophisticated analysis may involve video capture and slow-motion review, or a pressure plate assessment to examine force distribution across the plantar surface of the foot. A podiatrist or sports physiotherapist will also conduct a static assessment, examining foot posture, arch height, and the degree of subtalar joint mobility. Understanding whether the overpronation is structural or functional will guide treatment decisions considerably.

Footwear: The First Line of Defence

For many runners, appropriate footwear is the most accessible and immediately effective intervention. Motion control and stability running shoes are specifically designed to address overpronation. Stability shoes feature a denser foam or medial post on the inner side of the midsole, which resists the inward rolling of the foot and encourages a more neutral gait. Motion control shoes go further, offering maximum rigidity and support for severe overpronators.

The challenge lies in matching the runner to the right shoe. A runner with mild overpronation may benefit from a stability shoe, while a more severe case may require a motion control model. Many specialist running stores offer gait analysis services to help with this decision. It is worth noting that while appropriate footwear can significantly reduce injury risk, it addresses the symptom rather than the underlying cause and should ideally be used in conjunction with other interventions.

Orthotic Insoles

Custom or semi-custom foot orthotics are another widely used and clinically supported treatment for overpronation. A custom orthotic is manufactured from a cast or 3D scan of the individual’s foot and is designed to control subtalar joint motion, support the medial arch, and redistribute ground reaction forces more evenly. Research supports their effectiveness in reducing injury rates associated with overpronation, particularly for plantar fasciitis and medial tibial stress syndrome.

Off-the-shelf orthotics offer a more affordable alternative, though they lack the precision of custom devices. For runners with mild to moderate overpronation, a quality semi-rigid over-the-counter insole with arch support may provide adequate benefit. In either case, orthotics work best as part of a broader treatment strategy rather than as a standalone solution.

Strengthening the Intrinsic and Extrinsic Foot Muscles

Perhaps the most durable and long-term solution to functional overpronation lies in targeted strengthening. The muscles responsible for controlling pronation include the tibialis posterior, the flexor hallucis longus, the flexor digitorum longus, and the intrinsic foot muscles. When these structures are weak or inhibited, the passive structures of the foot — the plantar fascia, ligaments, and joint capsules — must bear a disproportionate load, leading to pain and injury.

A physiotherapist will typically prescribe exercises such as single-leg calf raises (which strengthen the tibialis posterior in its pronation-controlling role), arch doming exercises (which activate the intrinsic foot muscles), toe spread and grip exercises, and foot inversion work with resistance bands. Hip abductor and gluteal strengthening is also essential, as weakness here places greater demand on the foot and ankle to compensate during the stance phase of running.

These exercises require patience and consistency. Functional improvements are typically measured in weeks to months rather than days, and runners must often continue with maintenance exercises indefinitely to prevent recurrence.

Flexibility and Mobility Work

Tightness in the calf complex — particularly the gastrocnemius and soleus — is strongly associated with overpronation. When dorsiflexion (the ability to bring the foot upward toward the shin) is limited, the foot compensates by collapsing the arch inward to allow forward progression of the body over the foot. Restoring adequate calf flexibility through regular stretching, foam rolling, and soft tissue therapy can meaningfully reduce overpronation and associated injury risk.

Stretching of the plantar fascia itself, the Achilles tendon, and the hip flexors also contributes to improved lower limb mechanics in the overpronating runner.

Load Management and Gradual Return to Running

Regardless of the treatment approach, load management is critical. Overpronation-related injuries often flare up when training volume or intensity is increased too quickly. Runners experiencing pain should reduce mileage, avoid speed work and hill running temporarily, and allow adequate recovery time. A physiotherapist or coach can help design a structured return-to-running programme that gradually reintroduces load as strength and mechanics improve.

Overpronation is a complex biomechanical problem with multiple contributing factors, and its treatment demands a similarly multi-faceted approach. Appropriate footwear and orthotics can offer immediate symptom relief and injury prevention, while targeted strengthening and flexibility work address the underlying dysfunction. Effective management also requires proper assessment, patience, and a willingness to modify training in the short term in service of long-term performance and health. With the right strategy, the vast majority of runners who overpronate can continue to train and compete without significant interruption.

Os Tibiale Externum: The Hidden Bone of the Foot

The human foot is a marvel of anatomical engineering, comprising 26 bones, 33 joints, and more than 100 muscles, tendons, and ligaments working in concert to support the full weight of the body. Yet, for all this complexity, the foot occasionally harbours an additional, uninvited structure: the os tibiale externum, more commonly known as the accessory navicular. Though small and often overlooked, this sesamoid-like bone carries considerable clinical significance and has fascinated anatomists, podiatrists, and orthopaedic surgeons for centuries.

What Is the Os Tibiale Externum?

The os tibiale externum is an accessory ossicle — a supernumerary bone — located on the medial (inner) side of the foot, adjacent to the navicular bone. The navicular itself sits along the inner arch of the foot, articulating with the talus proximally and the three cuneiform bones distally. The os tibiale externum develops as a secondary centre of ossification within the substance of, or immediately adjacent to, the posterior tibial tendon’s insertion site on the navicular. It is encased within this tendon or connected to the navicular by a fibrous or fibrocartilaginous bridge, a junction known as a synchondrosis.

This accessory bone is one of the most common accessory ossicles found in the human foot, with an estimated prevalence of between 4% and 21% of the general population, depending on the imaging modality and study population used. It presents bilaterally — in both feet — in approximately 50 to 90% of affected individuals, suggesting a strong genetic underpinning. It is slightly more common in females than males, and it tends to become symptomatic during adolescence when the foot is undergoing rapid growth and the demands placed on the musculoskeletal system intensify.

Classification and Anatomy

Anatomists and clinicians have long recognised that the os tibiale externum does not present in a uniform fashion. The most widely accepted classification system divides it into three distinct types.

Type I is the smallest variant, a true sesamoid bone fully embedded within the posterior tibial tendon, typically measuring 2 to 3 millimetres. It sits entirely within the tendon substance and is usually an incidental finding on imaging, rarely causing symptoms.

Type II is the most clinically relevant variant and the one most commonly associated with pain. It is a larger ossicle, typically between 8 and 12 millimetres, connected to the navicular by a synchondrosis — a fibrocartilaginous union. This junction is biomechanically vulnerable. Under repetitive loading and torsional stress, the synchondrosis can become inflamed, develop microfractures, or fail entirely, producing the clinical syndrome known as accessory navicular syndrome or os tibiale externum syndrome.

Type III, sometimes called the cornuate navicular, represents a fully fused accessory ossicle that has united with the navicular proper. This produces a characteristically enlarged, horn-shaped navicular visible on plain radiographs. Because fusion has occurred, Type III is generally asymptomatic, though the altered morphology of the navicular may influence the mechanics of the arch.

Clinical Presentation and Symptoms

The os tibiale externum is often asymptomatic throughout an individual’s lifetime, discovered only incidentally on imaging performed for an unrelated reason. However, when symptoms do arise, they typically manifest as medial midfoot pain, tenderness directly over the navicular prominence, and swelling in the region of the inner arch. The overlying skin may become irritated, particularly in individuals who wear tight or poorly fitting footwear.

Symptoms most commonly emerge during adolescence, often coinciding with periods of rapid skeletal growth, increased physical activity, or both. Flat foot deformity — pes planus — is frequently associated with symptomatic accessory navicular, as a lowered medial longitudinal arch places the posterior tibial tendon under greater mechanical strain, transmitting increased stress across the synchondrosis. Activities that involve repeated inversion and eversion of the foot, such as running, dancing, and team sports, are common triggers.

Acute exacerbation can also result from direct trauma to the medial foot. A forced eversion injury — such as a rolled ankle — may stress or rupture the synchondrosis acutely, mimicking or co-existing with a navicular fracture and presenting a diagnostic challenge in the emergency setting. High-resolution imaging, including MRI, is invaluable in these scenarios, revealing bone marrow oedema, synchondral disruption, and tendon pathology that plain radiographs cannot adequately depict.

Diagnosis

Diagnosis begins with a thorough clinical assessment. A clinician will observe the contour of the medial arch, assess for the characteristic medial navicular prominence, and identify point tenderness with direct palpation. Functional assessment includes evaluating heel-rise capacity, assessing for pes planus, and examining the integrity and strength of the posterior tibial tendon.

Plain radiographs, particularly the medial oblique view, reliably demonstrate the ossicle and allow classification by type. MRI provides superior soft tissue resolution and is the gold standard for assessing the degree of synchondral inflammation, bone marrow changes, and posterior tibial tendon integrity. Technetium bone scintigraphy has historically been used to demonstrate increased uptake at the synchondrosis, confirming active stress response, though MRI has largely supplanted it in contemporary practice.

Treatment

Management is stratified according to symptom severity. Conservative treatment is the first-line approach and succeeds in the majority of cases. Rest, activity modification, and the use of non-steroidal anti-inflammatory medications can reduce acute inflammation. Orthotics designed to support the medial arch and offload the navicular prominence are particularly effective, redistributing stress away from the synchondrosis. Immobilisation in a short-leg cast or a removable walking boot is reserved for more severe or refractory presentations, allowing the inflamed synchondrosis to settle over a period of weeks.

When conservative measures fail after three to six months, surgical intervention becomes appropriate. The Kidner procedure — excision of the accessory ossicle with advancement and reattachment of the posterior tibial tendon to the navicular — remains the most commonly performed operation. Modern variations aim to preserve tendon function and restore medial arch support. Outcomes are generally favourable, with the large majority of patients reporting significant pain relief and a return to full activity.

The os tibiale externum is a small but clinically meaningful anatomical variant that sits at the intersection of embryology, biomechanics, and musculoskeletal medicine. Its presence is common, its expression variable, and its capacity to generate significant pain in active individuals well documented. Understanding its classification, the mechanisms by which it becomes symptomatic, and the spectrum of treatment options available allows clinicians to manage affected patients effectively — restoring comfort, function, and quality of life from a bone that, by rights, was never meant to be there at all.

The Treatment of Onychomycosis in the Foot

Onychomycosis — fungal infection of the nail — is one of the most prevalent dermatological conditions encountered in podiatric practice, accounting for approximately 50% of all nail disorders. It is caused primarily by dermatophytes, most commonly Trichophyton rubrum and Trichophyton mentagrophytes, though non-dermatophyte moulds and Candida species are increasingly recognised as causative organisms, particularly in immunocompromised individuals. The condition disproportionately affects the toenails over the fingernails, and its prevalence rises markedly with age, peripheral vascular disease, diabetes mellitus, and immunosuppression. Despite being perceived by some as a cosmetic nuisance, onychomycosis carries significant clinical implications including pain, difficulty ambulating, secondary bacterial infection, and considerable psychological distress. Effective management therefore demands a thorough, evidence-based approach.

Diagnosis Before Treatment

Accurate diagnosis is the essential prerequisite to any treatment programme. Clinical presentation alone — thickened, discoloured, dystrophic nails — is insufficient to confirm onychomycosis, as similar appearances can result from psoriasis, trauma, lichen planus, and other non-fungal conditions. Mycological confirmation via nail clippings sent for microscopy and culture remains the gold standard, with a sensitivity improved further by polymerase chain reaction (PCR) testing where available. Commencing antifungal therapy without laboratory confirmation risks not only treatment failure but unnecessary systemic drug exposure and cost.

Topical Antifungal Therapy

For mild to moderate onychomycosis — particularly distal and lateral subungual onychomycosis with less than 50% nail plate involvement and no matrix involvement — topical antifungal agents represent a reasonable first-line option. Amorolfine 5% nail lacquer, applied weekly, and ciclopirox 8% nail lacquer, applied daily, are the most widely used preparations. These agents penetrate the nail plate and exert their fungicidal activity directly at the site of infection, avoiding systemic side effects.

However, topical monotherapy has significant limitations. Penetration through the nail plate is inherently difficult, and cure rates with topical agents alone are modest — typically ranging from 5–15% mycological cure at 48 weeks for amorolfine monotherapy in distal subungual onychomycosis. Newer topical agents, including efinaconazole 10% solution and tavaborole 5% solution, demonstrate superior penetration profiles and have shown improved mycological cure rates in clinical trials, reaching 53% and 31% respectively in pivotal studies. These agents represent an advance in topical therapy, particularly for patients in whom systemic treatment is contraindicated.

Topical treatment is most effective when combined with nail debridement — the mechanical reduction of nail thickness — which reduces the fungal burden and improves drug penetration. Podiatrists routinely perform debridement as an adjunct to both topical and systemic treatment.

Systemic Antifungal Therapy

For moderate to severe onychomycosis, matrix involvement, or failure of topical therapy, systemic antifungal agents are the treatment of choice and offer substantially higher cure rates. Two oral agents dominate current practice: terbinafine and the triazole antifungals, principally itraconazole.

Terbinafine, an allylamine that inhibits squalene epoxidase and thus ergosterol synthesis, is considered the gold standard for dermatophyte onychomycosis. A continuous 12-week course for toenail infection achieves mycological cure rates of approximately 70–80%, with complete cure rates (mycological plus clinical) of around 35–50%. Its fungicidal rather than fungistatic mode of action and its high nail keratin affinity contribute to its efficacy. Terbinafine is generally well tolerated, though clinicians must remain alert to rare but serious adverse effects including hepatotoxicity and severe cutaneous reactions such as Stevens-Johnson syndrome. Baseline liver function testing is recommended in those with pre-existing liver disease.

Itraconazole, a triazole that inhibits cytochrome P450-dependent lanosterol 14?-demethylase, may be administered continuously (200 mg daily for 12 weeks) or via pulse dosing (400 mg daily for one week per month, for three pulses). Pulse therapy reduces drug accumulation and cost while retaining acceptable efficacy, with mycological cure rates of approximately 54–63% for toenail infection. Itraconazole has a broader spectrum of activity than terbinafine, making it preferable for non-dermatophyte and Candida-associated infections. Its significant cytochrome P450 3A4 inhibition creates numerous drug interactions, and its negative inotropic properties necessitate caution in patients with cardiac failure.

Fluconazole, administered weekly at 150–300 mg, represents an alternative for patients intolerant of or contraindicated to first-line agents, though evidence for its use in toenail onychomycosis is less robust.

Laser and Device-Based Therapies

Over the past decade, laser therapy has attracted considerable attention as a non-pharmacological treatment option. Nd:YAG lasers operating at 1064 nm, as well as diode and fractional CO2 lasers, have been investigated. The proposed mechanism involves selective photothermal destruction of fungal organisms within the nail. While short-term mycological improvement has been reported, systematic reviews have found the evidence for laser therapy to be of generally low quality, with heterogeneous methodologies and high recurrence rates. Laser treatment is not currently recommended as a primary therapy by major dermatological or podiatric guidelines, though it may have a role as an adjunct or in patients unable to tolerate pharmacological treatment.

Photodynamic therapy (PDT), using photosensitising agents activated by visible light, has also been explored with some promise, particularly for milder cases, but similarly awaits more robust evidence before entering mainstream practice.

Surgical and Mechanical Interventions

Surgical nail avulsion — partial or complete removal of the nail plate — is occasionally employed, particularly when there is marked thickening preventing adequate drug penetration, or in the context of painful subungual hyperkeratosis. Chemical avulsion using 40% urea preparations offers a less invasive alternative, softening and dissolving the nail plate over several weeks to facilitate drug delivery and reduce fungal burden.

Permanent nail ablation via matricectomy — chemical (phenol), surgical, or laser — may be considered in refractory cases or where quality of life is severely impacted by recurrent infection, accepting the consequence of permanent nail loss.

Recurrence and Prevention

Recurrence following successful treatment is a major challenge, affecting up to 50% of patients within five years. Contributing factors include re-infection from environmental reservoirs (shoes, socks, communal areas), concurrent tinea pedis, and host susceptibility factors. Long-term management must therefore incorporate prophylactic measures: antifungal foot powders, replacement of contaminated footwear, treatment of concurrent tinea pedis, and patient education on hygiene practices in communal bathing environments. In high-risk individuals — particularly those with diabetes or peripheral vascular disease — regular podiatric monitoring and preventive nail care are essential components of ongoing management.

The treatment of onychomycosis in the foot requires a patient-centred, stepwise approach guided by accurate diagnosis, severity assessment, and individual risk factors. While topical agents suffice for mild disease, systemic antifungals — principally terbinafine — remain the cornerstone of treatment for most cases. Mechanical debridement, adjunctive topical therapy, and preventive education are integral to achieving durable cure. Emerging technologies such as novel topical agents and laser therapy broaden the therapeutic landscape, though further evidence is needed to establish their definitive role. Given its high prevalence, tendency to recur, and impact on quality of life, onychomycosis warrants the careful, sustained clinical attention that effective podiatric practice affords.

Onitsuka Tiger: The Sole of a Legacy

There is a particular kind of cool that cannot be manufactured — it must be earned. Onitsuka Tiger has earned it over seven decades, threading its way from the rubble of postwar Japan to the feet of fashion editors, film icons, and athletes alike. It is a brand that has outlasted trends, survived corporate reinvention, and emerged not merely intact but celebrated. To wear Onitsuka Tiger is to participate in a lineage — part sporting history, part cultural mythology, entirely its own thing.

Origins in the Ashes

The story begins in Kobe, Japan, in 1949. Kihachiro Onitsuka was a young entrepreneur, thirty years old and possessed of a particular conviction: that sport could rebuild a nation’s spirit. Japan had just emerged from the devastation of World War II, and Onitsuka believed that physical activity — specifically, giving young people proper footwear for it — could restore a sense of purpose and dignity to a demoralised generation. He founded Onitsuka Co., Ltd. with modest capital and an almost missionary sense of purpose.

His first product was a basketball shoe, and it was here that one of footwear’s most charming origin stories was born. Struggling to design a sole that would grip the court effectively, Onitsuka reportedly found inspiration while eating octopus — the suction cups on the tentacles suggesting a pattern that could grip almost any surface. The resulting sole became a hallmark of early Onitsuka craftsmanship: functional, ingeniously observed, and rooted in everyday Japanese life.

The Tiger Stripes

By the mid-1950s, Onitsuka had shifted focus to running shoes, and in 1953 introduced the design element that would define the brand forever: the distinctive side stripe, or “tiger stripes,” that run diagonally from the sole up the lateral side of the upper. Originally a structural feature intended to reinforce the shoe, these stripes became the brand’s visual identity. Simple, bold, and immediately recognisable, they gave Onitsuka Tiger an aesthetic language that has never needed updating — only reinterpreting.

The 1960s were a period of intense global ambition. Onitsuka’s shoes were selected for Japanese athletes competing in the 1964 Tokyo Olympics, an extraordinary moment of national pride and international exposure. The shoes performed. Athletes noticed. The brand’s reputation spread beyond Japan’s borders, reaching American and European markets at a moment when running culture was beginning its long ascent into mainstream consciousness.

The American Connection

The American chapter of Onitsuka Tiger’s story involves a young accounting student named Phil Knight, who would later co-found Nike. In 1962, Knight visited the Onitsuka factory in Kobe and negotiated the rights to distribute Tiger shoes in the United States under the name Blue Ribbon Sports. For nearly a decade, Onitsuka Tigers were the performance running shoe of choice among serious American athletes — before the relationship fractured and Knight went on to build his own empire.

This episode, dramatised in Knight’s memoir Shoe Dog and later in the television series Full Count, is a reminder of how central Onitsuka Tiger was to the birth of global sneaker culture. The brand was not peripheral to that story — it was the inciting incident. It taught an American entrepreneur what a great athletic shoe could be, and the lessons learned on those Kobe factory floors rippled outward to shape the entire industry.

Kill Bill and the Cultural Moment

No account of Onitsuka Tiger’s cultural life would be complete without Quentin Tarantino. In 2003, Kill Bill: Volume 1 placed a pair of yellow and black Onitsuka Tiger Mexico 66s on Uma Thurman’s feet as she carved her way through the Crazy 88. The shoe — sleek, retro, undeniably cool — became the film’s most imitated fashion detail almost overnight. Orders surged. A generation of cinephiles who had never heard of Onitsuka Tiger went looking for those yellow shoes.

It was a masterclass in accidental branding, or perhaps deliberate brilliance — Tarantino is, after all, a connoisseur of authentic cool. The Mexico 66, originally launched in 1966 and named for the Mexico City Olympics, is now the brand’s most iconic silhouette: low-profile, clean-lined, with just enough vintage character to feel both nostalgic and current. It has been reissued in hundreds of colourways and remains one of the most recognisable shoes in the sneaker world.

The Asics Years and Renewed Independence

In 1977, Onitsuka merged with two other companies to form Asics — a name derived from the Latin phrase Anima Sana In Corpore Sano, meaning “a healthy soul in a healthy body.” For years, the Onitsuka Tiger brand was largely dormant, subsumed into Asics’ performance athletic identity. It was relaunched as a lifestyle and fashion label in 2002, operating under the Asics umbrella but with its own distinct creative direction — retro-influenced, fashion-forward, and firmly pointed at a different consumer than the serious runner reaching for Asics Gel-Kayanos.

This distinction matters. Onitsuka Tiger occupies a unique position: it carries the credibility of genuine athletic heritage without pretending to be a performance brand. It is honest about its identity — a fashion label grounded in history — and that honesty is part of its appeal. In an era when many brands manufacture heritage they don’t actually possess, Onitsuka Tiger’s decades of real history function as a kind of luxury.

Design Philosophy and Contemporary Appeal

Today, Onitsuka Tiger’s design language balances reverence and reinvention. The core archive — Mexico 66, California 78, Serrano, Fabre — is treated with curatorial seriousness, with seasonal colourways and collaborations that refresh without undermining. Collaborations with designers including Andrea Pompilio and Walter Van Beirendonck have positioned the brand firmly within high fashion, while the mainline collection maintains accessibility.

The shoes themselves remain distinctively Japanese in their construction philosophy: meticulous, considered, and attentive to materials. There is a quietness to Onitsuka Tiger design — a preference for understatement that reads as confidence rather than timidity. Where many sneaker brands scream for attention, Onitsuka Tiger tends to murmur, and somehow people lean in to listen.

A Legacy Still Being Written

What makes Onitsuka Tiger enduring is not nostalgia alone, though nostalgia plays its part. It is the coherence of a brand that has always known what it believed in: the dignity of craft, the beauty of functional design, the idea that a shoe can carry meaning beyond its materials. Kihachiro Onitsuka wanted to rebuild a nation’s spirit through sport. He built something longer-lasting than he likely imagined — a pair of stripes that still, seventy-five years on, mean something to the people who wear them.

That is a rare kind of legacy. And it fits perfectly.

Heavy Burdens: How Obesity Affects the Feet

The human foot is an engineering marvel — a complex structure of 26 bones, 33 joints, and more than 100 muscles, tendons, and ligaments, all working in precise coordination to bear the weight of the body with every step. But that marvel has limits. When excess body weight is placed upon it year after year, the foot begins to fail in ways that are painful, progressive, and often underappreciated. Obesity — defined as a body mass index (BMI) of 30 or above — places enormous mechanical and systemic stress on the feet, contributing to a wide range of conditions that can profoundly diminish quality of life.

The Mechanical Burden

The most immediate way obesity harms the feet is through sheer mechanical load. During normal walking, each foot absorbs a force equivalent to roughly 1.25 times a person’s body weight with every step. During running or stair climbing, that force can multiply to three or four times body weight. For someone who is obese, this means the structures of the foot are subjected to vastly greater pressure than they were designed to handle, day after day, year after year.

This sustained overloading has consequences at every level. The arches of the foot — the medial longitudinal arch in particular — are placed under exceptional strain. The plantar fascia, the thick band of connective tissue that supports the arch and runs from the heel to the base of the toes, becomes chronically stretched and inflamed. The result is plantar fasciitis, one of the most common and debilitating foot conditions in the world, and one that is significantly more prevalent among people with obesity. Sufferers typically experience a stabbing pain in the heel, worst during the first steps of the morning, that can persist for months or years if left untreated.

Related to plantar fasciitis is the progressive flattening of the foot that accompanies obesity. As the arch collapses under excess weight, the foot pronates — rolling inward — changing the biomechanics of the entire lower limb. This altered gait does not stay confined to the foot. It places additional stress on the ankles, knees, hips, and lower back, creating a cascade of musculoskeletal problems that often accompany obesity-related foot dysfunction.

Joint Disease and Arthritis

Obesity is one of the strongest modifiable risk factors for osteoarthritis, and the joints of the foot are not exempt. The subtalar joint, the midfoot joints, and the metatarsophalangeal joints — particularly that of the big toe — all bear excess load in obese individuals. Over time, the cartilage that cushions these joints wears away, leading to pain, stiffness, swelling, and reduced range of motion.

Gout, a form of inflammatory arthritis caused by the accumulation of uric acid crystals in joints, is also strongly associated with obesity. The big toe joint is the classic site of a gout attack, which presents as sudden, excruciating pain, redness, and swelling so severe that even the weight of a bed sheet can be intolerable. Obesity promotes hyperuricemia — elevated uric acid in the blood — by reducing the kidneys’ ability to excrete uric acid and by increasing its production through metabolic pathways linked to excess fat tissue.

Vascular and Neuropathic Complications

Obesity is a primary driver of type 2 diabetes, and the feet are among the organs most devastated by diabetic complications. Peripheral arterial disease — the narrowing of blood vessels in the legs and feet — reduces circulation to the extremities. At the same time, peripheral neuropathy damages the nerves of the feet, causing pain, tingling, numbness, or a complete loss of sensation.

The combination of poor circulation and reduced sensation is particularly dangerous. Minor injuries — a blister, a small cut, a pressure sore — may go unnoticed and untreated because the patient cannot feel them. Without adequate blood supply to support healing and immune defence, these wounds can develop into chronic ulcers that resist treatment. In severe cases, infection spreads to underlying bone and tissue, and amputation becomes necessary. Lower limb amputations are among the most feared and devastating complications of diabetic foot disease, and obesity is a central driver of the diabetes that precedes them.

Skin and Soft Tissue Problems

The feet of people with obesity are also vulnerable to a range of skin and soft tissue problems. Increased sweating and skin-to-skin contact in skin folds can create warm, moist environments in which fungal infections — particularly tinea pedis, or athlete’s foot — thrive. These infections cause itching, scaling, and cracking of the skin, and if left untreated, can open pathways for bacterial invasion.

Calluses and corns develop in response to the abnormal pressure patterns created by excessive body weight and altered gait. While these are the body’s attempt to protect vulnerable skin, they can themselves become painful and, in diabetic patients, can progress to ulceration. Swelling of the feet and ankles — peripheral oedema — is also common in obesity, resulting from both the mechanical obstruction of lymphatic and venous return by excess tissue and from the cardiac and renal strain that frequently accompanies chronic obesity.

Psychological and Social Dimensions

The impact of obesity-related foot problems extends beyond the purely physical. Chronic foot pain limits mobility, making exercise more difficult — which in turn makes weight management harder, creating a vicious cycle that can feel impossible to escape. Reduced physical activity contributes to social isolation, depression, and a declining sense of self-efficacy. Shoe fitting becomes a practical challenge as foot shape changes, and the indignity of limited footwear options adds to the psychological burden.

For many people, foot pain is not merely an inconvenience but a barrier to participation in ordinary life: shopping, walking with family, standing at work. When the feet fail, independence erodes.

A Path Forward

Understanding the profound impact of obesity on foot health underscores the importance of early intervention and preventive care. Weight reduction — even modest losses of five to ten percent of body weight — measurably reduces the mechanical load on the feet and can significantly alleviate plantar fasciitis, joint pain, and swelling. Appropriate footwear, custom orthotics, physiotherapy, and regular podiatric care can help manage existing conditions and prevent deterioration.

Ultimately, the feet are both victims and messengers. The pain they generate is a signal that the body is under systemic strain — strain that, if addressed, can be reduced. The connection between obesity and foot health is a compelling reminder that the consequences of excess weight are not abstract or distant, but immediate, concrete, and felt with every step.

Nocturnal Leg Cramps: Understanding the Night-Time Intruder

Few experiences are as jarring as being woken from a deep sleep by a sudden, vice-like pain seizing the muscles of the leg. This is the hallmark of nocturnal leg cramps (NLCs) — involuntary, painful muscle contractions that occur at night, most commonly in the calf, though the thighs and feet are not immune. Known colloquially as “charley horses,” these episodes are far more than a minor inconvenience. For millions of people worldwide, they represent a chronic disruption to sleep, wellbeing, and quality of life. Understanding their prevalence, causes, mechanisms, and management is essential — not only for those who experience them, but for the health professionals who support them.

Prevalence and Who Is Affected

Nocturnal leg cramps are remarkably common. Research indicates that between 50 and 60 percent of adults report experiencing them at some point, with approximately 30 percent of adults experiencing them at least five times per month. They affect both sexes, though they are slightly more prevalent among women, and their frequency increases considerably with age. Children are not entirely spared — around 7 percent of children also report nocturnal cramps — but the condition is predominantly one of adulthood and older age. Concerningly, up to 20 percent of sufferers experience symptoms bothersome enough to seek medical attention, speaking to the very real impact these episodes can have on daily functioning and mental health.

What Happens During a Cramp?

A nocturnal leg cramp is an involuntary contraction of a muscle that occurs without the individual’s intention or control. The episode typically begins suddenly and without warning. The muscle — most often the gastrocnemius (the large calf muscle) or the soleus beneath it — tightens into a hard, palpable knot. The pain can be severe, lasting on average around nine minutes per episode, though in some cases it may persist longer. Even after the spasm passes, residual soreness and tenderness can linger for hours, sometimes for the remainder of the following day. When cramps recur across multiple nights, or cluster in episodes throughout a single night, the cumulative sleep disruption can contribute to secondary insomnia, daytime fatigue, anxiety about sleep, and reduced overall wellbeing.

Causes and Contributing Factors

The precise mechanism behind nocturnal leg cramps remains incompletely understood, but research points most strongly to muscle fatigue and nerve dysfunction as the primary drivers, rather than the electrolyte imbalances that are commonly assumed to be responsible. That said, the picture is rarely simple, and a range of factors — lifestyle, medical, and pharmacological — can heighten an individual’s susceptibility.

Lifestyle and postural factors play a significant role. Prolonged sitting, particularly in positions that shorten the calf muscles, reduces blood supply to the legs and increases cramping risk. Standing for long periods on hard surfaces such as concrete has a similar effect. Sleeping in the supine position with feet pointed downward (plantar flexion) shortens the calf muscles during rest, making nocturnal spasms more likely. Conversely, overexertion — too much high-intensity physical activity — can fatigue the muscles sufficiently to trigger cramping during the subsequent night’s rest.

Medical conditions associated with nocturnal leg cramps include peripheral vascular disease, lumbar spinal stenosis, liver cirrhosis, chronic kidney failure, diabetic peripheral neuropathy, hyperthyroidism, and electrolyte disturbances such as low calcium or elevated potassium. Pregnancy is also a well-recognised trigger, particularly in the later trimesters. Notably, while these associations are clinically important to identify, the evidence does not always show that treating the underlying condition reliably resolves the cramps — suggesting the relationship is complex and multifactorial.

Medications are another important contributor. Several pharmacological agents are strongly associated with nocturnal leg cramps, including intravenous iron sucrose, conjugated oestrogens, raloxifene, naproxen, teriparatide, diuretics, statins, and corticosteroids. Clinicians should review a patient’s medication history when cramps are a presenting complaint, as substituting or adjusting the implicated drug may bring meaningful relief.

Differential Diagnosis

Not all nocturnal leg pain is caused by true muscle cramps. Several conditions can mimic or be confused with Nocturnal leg cramps, and accurate diagnosis is essential. Restless legs syndrome (RLS) is perhaps the most commonly confused alternative — it involves an urge to move the legs rather than a painful contraction and is typically relieved by movement rather than muscle stretching. Peripheral arterial claudication causes leg pain on exertion and is related to ischaemia. Myositis (muscle inflammation) and peripheral neuropathy can also produce leg discomfort at night. A thorough history and physical examination are usually sufficient to differentiate these conditions; laboratory investigations and specialised testing are rarely required to confirm Nocturnal leg cramps.

Management and Treatment

Managing nocturnal leg cramps encompasses both immediate relief and longer-term prevention. When a cramp strikes, the most effective immediate intervention is to stretch the affected muscle. For a calf cramp, this involves flexing the foot upward (dorsiflexion) — standing up and pressing the heel flat to the floor, or pulling the toes upward while seated. Massaging the area and applying warmth can also help relax the muscle and alleviate pain more quickly.

For prevention, a programme of regular calf and lower limb stretching — especially before bed — has good evidence behind it. Reviewing sleeping posture to avoid sustained plantar flexion is also beneficial; some individuals find that sleeping with a pillow to prop the feet in a neutral position reduces frequency. Staying well hydrated and avoiding excessive exercise in the hours before bed may further reduce risk.

In cases where cramps are frequent and disruptive, pharmacological options have been explored. Historically, quinine was widely prescribed and found to be effective, but its use is now restricted in many countries due to serious cardiac side effects. Magnesium supplementation, vitamin B complex, gabapentin, and muscle relaxants such as carisoprodol or orphenadrine have all been trialled with varying degrees of success. No single pharmacological agent has emerged as universally preferred, and treatment should always be individualised with reference to the patient’s overall health profile and comorbidities.

The Role of the Podiatrist

Podiatrists are particularly well-positioned to assess and manage nocturnal leg cramps given their expertise in lower limb biomechanics, footwear, and neuromuscular function. Gait analysis can reveal postural contributors to muscle fatigue; orthotic intervention may reduce strain on the calf and foot musculature; and foot positioning advice can minimise cramping during sleep. Podiatrists also serve an important role in identifying when Nocturnal leg cramps may be symptomatic of vascular or neurological conditions warranting referral to other specialists.

Nocturnal leg cramps are a common, often underestimated clinical problem with real consequences for sleep, mood, and daily life. While frequently benign and idiopathic, they may in some cases reflect underlying medical conditions or medication effects that warrant investigation. A thoughtful approach — combining patient education, lifestyle modification, postural strategies, stretching, and where appropriate, pharmacological support — offers the best chance of meaningful, sustained relief. No one should simply accept that disruptive nights of pain are inevitable.

Night Splints in the Treatment of Plantar Fasciitis 

Plantar fasciitis is the most common cause of heel pain in adults, affecting an estimated one in ten people at some point during their lifetime. Characterised by degeneration and inflammation of the plantar fascia at its proximal insertion on the medial calcaneal tubercle, the condition produces a well-recognised clinical pattern: sharp, stabbing heel pain that is most intense with the first steps of the morning or after periods of prolonged rest. This "post-static dyskinesia" is the hallmark of the condition and provides the conceptual basis for one of its most widely used conservative treatments — the night splint.

Night splints have been a mainstay of plantar fasciitis management for several decades. By maintaining the foot and ankle in a position of dorsiflexion throughout sleep, they aim to counteract the pathological processes that underlie morning pain. Understanding why night splints work requires an appreciation of the biomechanical and histological mechanisms driving the condition, and their clinical application is best understood within the broader context of evidence-based conservative care.

## Pathophysiology and the Rationale for Night Splints

The plantar fascia functions as a passive tension band along the undersurface of the foot, supporting the medial longitudinal arch and facilitating efficient propulsion during gait. Repetitive mechanical loading — particularly in individuals with limited ankle dorsiflexion, excessive body weight, prolonged weight-bearing occupations, or biomechanical abnormalities such as pes planus or pes cavus — leads to cumulative microtrauma at the fascial origin. This produces a cycle of failed healing and degenerative change rather than true acute inflammation, a process more accurately termed plantar fasciopathy in contemporary literature.

During sleep, the foot naturally rests in a position of plantarflexion. In this position, the plantar fascia and the intrinsic musculature of the foot are in a shortened, relaxed state. When the individual rises and bears weight, the sudden tensile loading of these contracted structures produces the characteristic pain of the first steps. Over time, nocturnal shortening may contribute to ongoing fascial tightness and impair the tissue's capacity for repair.

The night splint directly addresses this mechanism. By holding the ankle in a neutral or mildly dorsiflexed position — typically five to fifteen degrees — throughout the sleeping hours, the device maintains a gentle, sustained stretch on both the plantar fascia and the Achilles tendon-gastrocnemius-soleus complex. This prolonged low-load stretching promotes fascial elongation, reduces morning contracture, and — according to some researchers — may facilitate the remodelling of collagen fibres within the healing tissue. The result, for many patients, is a meaningful reduction in first-step pain and an improvement in overall function.

## Types of Night Splints

Night splints are available in two principal designs: posterior splints and anterior (or dorsal) splints.

Posterior night splints are the traditional design, consisting of a rigid or semi-rigid shell that runs along the back of the lower leg and under the foot, secured with straps. They hold the ankle in dorsiflexion and are effective at maintaining the desired position throughout the night. However, their bulk and rigidity are frequently cited by patients as uncomfortable, leading to poor compliance — a critical limitation in any treatment that requires nightly use over an extended period.

Anterior or dorsal night splints address this concern by positioning the shell along the front of the lower leg and the dorsum of the foot, leaving the heel and posterior calf free. Patients generally report these to be more comfortable and less disruptive to sleep, and compliance rates tend to be higher. A third variant, the sock-style or "strassburg sock," applies a gentle dorsiflexion force through a strap connected from the toe of a compression sock to the knee. While less rigid than splinted designs, it is particularly well tolerated and has demonstrated efficacy in clinical trials.

The choice between designs should be guided by individual patient factors, including tolerance, sleep position, and the degree of ankle dorsiflexion restriction. Fitting and patient education are essential: the splint must be worn consistently — ideally every night — for a minimum of one to three months to achieve meaningful benefit.

## Clinical Evidence

The evidence supporting night splints for plantar fasciitis is generally positive, though the quality of available research is variable. Multiple randomised controlled trials and systematic reviews have demonstrated that night splints produce significant reductions in pain and improvements in function compared to baseline, and are broadly comparable to other conservative interventions such as stretching programmes, orthotics, and corticosteroid injections in terms of short-to-medium-term outcomes.

A landmark study by Batt, Tanji, and Skattum demonstrated that patients using night splints alongside a standard stretching programme achieved superior outcomes compared to stretching alone. Similarly, a well-cited trial by Powell and colleagues found that night splints were significantly more effective than anti-inflammatory medication and activity modification in reducing first-step pain at eight weeks. The Strassburg sock has been evaluated in a prospective controlled trial, with results showing resolution of symptoms in the majority of participants within a mean of approximately eight weeks.

Notably, night splints appear to be particularly effective for patients with chronic plantar fasciitis — defined as symptoms persisting for more than six months — who have failed to respond to other conservative measures. In this subgroup, the addition of a night splint to an existing treatment programme frequently produces the breakthrough improvement that other modalities alone had not achieved.

## Integration into a Treatment Plan

Night splints are rarely employed in isolation. Best practice dictates their use as part of a multimodal conservative approach that may include calf and plantar fascia stretching, load management, foot orthoses, footwear modification, and — where indicated — shockwave therapy or physiotherapy-guided exercise rehabilitation. Patient education regarding the chronic, self-limiting nature of the condition, combined with realistic expectations about the timeline for recovery, is fundamental to engagement and adherence.

Compliance remains the single greatest barrier to success with night splint therapy. Clinicians should discuss this openly with patients, acknowledge the challenges of wearing a device during sleep, and explore which design is most likely to suit the individual's lifestyle and sleeping habits.


Night splints represent a well-established, biomechanically rational, and evidence-supported intervention in the conservative management of plantar fasciitis. By maintaining a sustained dorsiflexion stretch throughout the night, they directly target the nocturnal fascial shortening that underlies the condition's most disabling symptom — first-step morning pain. When appropriately selected, correctly fitted, and used consistently as part of a comprehensive treatment programme, night splints can produce meaningful clinical improvement and accelerate recovery, particularly in patients with chronic or refractory symptoms. They remain a valuable and accessible tool in the podiatric and sports medicine clinician's armamentarium.

New Balance Running Shoes: A Legacy Built One Step at a Time

In the crowded world of athletic footwear, few brands have managed to build a reputation as enduring and respected as New Balance. While names like Nike and Adidas dominate pop culture and billion-dollar marketing campaigns, New Balance has carved out a distinctive identity rooted in something more fundamental: the quality of the run itself. From the dedicated marathoner logging pre-dawn miles to the casual jogger finding their stride on a weekend morning, New Balance running shoes have become synonymous with comfort, performance, and a quiet kind of authenticity that resonates deeply with those who take their running seriously.

A Brand Born from the Ground Up

New Balance was founded in Boston, Massachusetts, in 1906 — not as a shoe company, but as an arch support manufacturer. William Riley created flexible arch supports inspired by a chicken’s foot, believing that the natural balance a bird achieves through its three-pronged stance could be replicated in footwear for humans. It was a humble beginning, but it planted the seed of a philosophy that would define the brand for over a century: that the foundation of great movement starts from the ground up.

It wasn’t until the 1960s that New Balance pivoted decisively toward running shoes, producing some of the first performance-oriented trainers aimed at serious runners. By 1976, their Trackster model was named the best running shoe on the market by a leading sports magazine — a landmark moment that announced New Balance as a genuine force in athletic footwear. The brand had arrived, and it had done so on the merits of its product rather than the power of celebrity endorsements.

The Philosophy of Fit

One of the most distinguishing features of New Balance’s approach to running shoes is its commitment to fit diversity. While many competitors offer shoes in standard widths, New Balance has long provided options ranging from narrow (2A) to extra-wide (4E and beyond). This seemingly simple decision reflects a profound understanding of the runner: that feet come in all shapes and sizes, and a shoe that doesn’t fit correctly is not just uncomfortable — it can be the source of injury, inefficiency, and discouragement.

For runners with wide feet, flat arches, or other anatomical considerations that fall outside the “average,” finding a well-fitting running shoe can feel like a nearly impossible task. New Balance has consistently addressed this gap, making the brand a trusted ally for runners who have long been overlooked by mainstream athletic footwear. This inclusive approach has cultivated fierce brand loyalty, particularly among older runners, long-distance athletes, and those returning to running after injury.

Flagship Models and Technological Innovation

New Balance’s running lineup spans a wide spectrum, from lightweight racing shoes to heavily cushioned daily trainers, and the brand has invested significantly in developing proprietary technologies to underpin each category.

The Fresh Foam platform, introduced in 2014, represents one of the brand’s most successful innovations. Using data-driven design and advanced computational modelling, Fresh Foam midsoles are engineered to deliver a plush, cushioned ride that adapts naturally to the runner’s gait. The Fresh Foam X 1080 — widely considered the pinnacle of the Fresh Foam line — is a shoe that has earned a devoted following among long-distance runners and those who demand maximum comfort on high-mileage training days. Its generous stack height and smooth, rolling ride make it a trusted companion for marathon training and recovery runs alike.

On the performance end of the spectrum, the FuelCell series brings a different energy to the table. FuelCell foam is engineered for propulsion, offering a firmer, more responsive feel that suits faster-paced training and racing. The FuelCell Rebel and FuelCell SuperComp Trainer have become go-to options for runners who want speed without sacrificing the reliability that New Balance is known for. The SuperComp Trainer, featuring a carbon fibre plate embedded within the midsole, places New Balance firmly in the elite category of super-shoes that have transformed competitive distance running in recent years.

The 860 and 880 series serve as the backbone of New Balance’s stability and neutral trainer offerings respectively. These workhorse shoes have evolved through numerous iterations while retaining the core qualities that made them popular — reliable structure, durable outsoles, and a consistent, trustworthy ride that day-after-day runners can depend on.

Made in the USA: A Commitment Worth Noting

In an era when nearly all athletic footwear is manufactured in Asia, New Balance stands apart as one of the only major brands to still produce shoes domestically. Their New England factories — located in Massachusetts and Maine — continue to manufacture a range of shoes on American soil, employing skilled workers and maintaining quality control practices that the brand considers a point of genuine pride.

This is not simply a marketing talking point. New Balance’s domestic manufacturing represents a tangible commitment to a different kind of value system — one that prioritises craftsmanship, local employment, and long-term quality over short-term cost reduction. For many consumers, knowing that their shoes were made by American workers in American factories adds a layer of meaning to their purchase that no amount of celebrity sponsorship can replicate.

The Cultural Moment

In recent years, New Balance has experienced something of a cultural renaissance. Once affectionately (and sometimes mockingly) associated with middle-aged dads and sensible footwear choices, the brand has undergone a remarkable reappraisal in style circles. Collaborations with high-fashion designers, limited-edition colourways, and organic adoption by streetwear communities have repositioned New Balance as a genuinely cool brand — one that has earned its cultural cachet without abandoning its roots.

Crucially, this cultural elevation has not come at the expense of performance. The same shoes that appear on fashion runways and in lifestyle editorials are the same shoes trusted by elite athletes and everyday runners. New Balance has managed the rare feat of becoming both fashionable and functional — a balance (fittingly) that many brands struggle to achieve.

New Balance running shoes endure because they are built on a foundation of genuine purpose. From their early days as arch support specialists to their current status as one of the most respected names in performance running, the brand has remained anchored to the belief that a great shoe exists to serve the runner — not the other way around. With a commitment to fit diversity, technological innovation, domestic manufacturing, and authentic performance, New Balance has earned its place not just on the feet of millions of runners, but in the broader story of what it means to move well. In a world of noise and spectacle, New Balance keeps things simple: lace up, step out, and run.

The Neuropad Test: Assessing Diabetic Peripheral Neuropathy at the Point of Care

Diabetic peripheral neuropathy (DPN) is one of the most prevalent and debilitating complications of diabetes mellitus, affecting up to 50% of people living with the condition over their lifetime. It is a major driver of foot ulceration, lower limb amputation, and cardiovascular autonomic dysfunction, carrying significant burdens for both patients and healthcare systems. Early, accurate detection is therefore critical — yet standard neurological assessments can be time-consuming, require specialist equipment, and are poorly suited to routine clinical settings. Into this gap has stepped the Neuropad, a simple, point-of-care indicator test that detects sudomotor (sweat gland) dysfunction as a proxy marker for small autonomic nerve fibre damage. Understanding how it works, what the evidence says, and where it fits in clinical practice is essential for clinicians managing diabetes.

How Neuropad Works

Neuropad is a small adhesive plaster developed by TRIGOcare International and designed for application to the plantar (sole) surface of the foot. The pad contains anhydrous cobalt (II) chloride — a blue compound that undergoes a well-characterised colour change when it absorbs water. When applied to the skin for ten minutes, a normal sudomotor response causes the pad to turn from blue to pink, reflecting adequate moisture from sweat glands. An abnormal or incomplete colour change — the pad remaining blue or turning only partially pink — indicates reduced or absent sweating, which is a hallmark of small autonomic C-fibre dysfunction.

The test is patented as a ten-minute screening tool for early detection of diabetic foot syndrome. It is non-invasive, painless, and requires no specialised equipment beyond the plaster itself, making it readily deployable in primary care, diabetes clinics, or even as a patient self-test at home. At a list price of approximately £7.28 per test (as assessed by NICE), it is substantially more affordable than nerve conduction studies or skin biopsy.

The Scientific Basis: Sudomotor Dysfunction in Neuropathy

Sweating in the feet is regulated by postganglionic cholinergic sympathetic nerve fibres — small, unmyelinated C-fibres that are among the earliest structures damaged in diabetic neuropathy. Sudomotor dysfunction therefore represents an early and sensitive marker of neuropathic change, often preceding clinical symptoms and detectable deficits in large-fibre tests such as vibration perception or nerve conduction velocity.

This biological rationale lends Neuropad particular relevance to the detection of small-fibre neuropathy — a form of DPN that traditional assessments poorly capture. Established tools such as the Neuropathy Disability Score (NDS) and nerve conduction studies (NCS) predominantly assess large myelinated fibres, and can miss early small-fibre involvement entirely.

Diagnostic Performance

The evidence base for Neuropad has grown substantially over the past two decades, with numerous clinical studies examining its sensitivity, specificity, and correlation with established neuropathy markers.

A landmark 2008 study by Quattrini et al., published in Diabetologia, evaluated 57 diabetic patients using Neuropad alongside quantitative sensory testing, autonomic function assessments, and intra-epidermal nerve fibre density from skin biopsy. The results demonstrated meaningful correlations between Neuropad responses and the NDS, neuropathic symptom scores, cold detection thresholds, and deep-breathing heart rate variability — reflecting both somatic and autonomic neuropathic involvement.

Subsequent studies have further characterised its performance profile. Across assessments against large-fibre neuropathy markers — such as the NDS and peroneal motor nerve conduction velocity — Neuropad demonstrates high sensitivity (typically 80–95%) but moderate specificity (50–70%). This pattern makes it well-suited as a screening tool: a normal result reliably reduces the likelihood of clinically significant neuropathy, but an abnormal result warrants further investigation.

Importantly, diagnostic accuracy is meaningfully improved when Neuropad is assessed against small-fibre measures. A 2014 study by Ponirakis and colleagues found that, compared with corneal nerve fibre length — a sensitive marker of small-fibre damage assessed by corneal confocal microscopy — Neuropad achieved a sensitivity of 83% and specificity of 80%, with an area under the ROC curve (AUC) of 85%. This outperformed its performance against both the NDS (AUC 66%) and peroneal motor nerve conduction velocity (AUC 70%), underscoring the test’s specific utility for small C-fibre assessment.

An important refinement involves moving beyond simple binary (pink/blue) interpretation to quantifying the rate of colour change. A study examining automated image analysis (Sudometrics) demonstrated that continuous colour-change output substantially improved diagnostic accuracy, achieving high sensitivity and specificity for autonomic dysfunction (91% and 83% respectively) and small-fibre neuropathy (88% and 78%), compared with the weaker specificity of the categorical reading alone.

Research has also established Neuropad’s reproducibility. A study in 142 type 2 diabetic patients found a highly significant correlation (r = 0.91) between repeat measurements of time to complete colour change, indicating strong test-retest reliability.

Autonomic Neuropathy and Cardiovascular Risk

Beyond peripheral neuropathy, Neuropad has been evaluated as a tool for detecting cardiovascular autonomic neuropathy (CAN) — a potentially life-threatening condition associated with silent myocardial ischaemia, arrhythmia, and increased mortality. Time to complete colour change correlates significantly with the Valsalva ratio, a standard autonomic function test, as well as with symptoms of DPN and postural hypotension. A cut-off of fifteen minutes for complete colour change has been identified as an optimal threshold, improving specificity for both CAN and DPN without compromising sensitivity.

Given that CAN often goes undetected until advanced stages, the ability of a simple plaster to prompt further autonomic evaluation is clinically meaningful.

Limitations and Clinical Considerations

Neuropad is not without limitations. Its moderate specificity, particularly against large-fibre assessments, means a positive result should not be used in isolation for diagnosis. Environmental factors — ambient temperature, skin moisture, and humidity — may influence the rate and completeness of colour change, adding variability to qualitative readings. Age, BMI, renal function, and alcohol use have also been identified as potential confounders of sudomotor function independent of glycaemic status.

In elderly populations with diabetes or pre-diabetes, the KORA F4 survey found reasonable sensitivity but low specificity for polyneuropathy diagnosis, with a positive predictive value as low as 33.6%. This supports positioning Neuropad as a triage or exclusion test rather than a standalone diagnostic.

NICE evaluated Neuropad under its Medical Technologies Guidance programme (MTG38, 2018), recommending it as an option for detecting early DPN, particularly in settings where more specialised testing is unavailable. The guidance acknowledged its ease of use and potential value in identifying patients who require further assessment.

Conclusion

The Neuropad test occupies a valuable niche in the clinical assessment of diabetic neuropathy. By providing a simple, inexpensive, and non-invasive window into sudomotor and small C-fibre function, it enables early detection of neuropathic changes that traditional large-fibre assessments routinely miss. Its high sensitivity makes it particularly effective as a screening and exclusion tool, and its performance improves markedly when interpreted quantitatively or benchmarked against small-fibre measures. While it should not replace comprehensive neurological evaluation, Neuropad represents a practical and evidence-based addition to the diabetic foot assessment toolkit — one that can meaningfully support earlier intervention and reduce the risk of serious complications.